Phibro Q4 adj diluted EPS up 5% to $0.38; full-year net income down 34%

PHIBRO ANIMAL HEALTH CORP

Q4 net sales $255.0M (flat YoY); net income $11.5M (+54%); adj diluted EPS $0.38 (+5%).
FY2023 net sales $977.9M (+4%); net income $32.6M (-34%); adj diluted EPS $1.21 (-8%).
FY2024 guidance: net sales $1.0-1.05B; adj EBITDA $115-121M; adj diluted EPS $1.12-1.27.
Animal Health FY sales +9% to $659.9M; Mineral Nutrition -6%; gross leverage 4.2x.
Free cash flow negative $24M; liquidity $248M; pension settlement to incur ~$10.4M expense in Q1 FY2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

PHIBRO ANIMAL HEALTH CORP updated its the fiscal quarter and fiscal year ended June 30, 2023 guidance (initiated).

Period: the fiscal quarter and fiscal year ended June 30, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter and fiscal year ended June 30, 2023 and its financial guidance for the fiscal year ending June 30, 2024.

View on SEC.gov

Browse all earnings releases →

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001558370-23-015362

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.